ECMM Candida Registry - CandiReg

University of Cologne2,000 enrolled

Overview

The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive Candida infections and to function as a platform for future studies and in case of outbreaks.

The specific objectives are: To describe the global incidence of invasive Candida infection To monitor trends globally and locally over time To define patient risk groups To assess antifungal resistance among Candida spp. causing invasive diseases worldwide To assess attributable mortality of invasive Candida infection To assess incremental costs associated with invasive Candida infection To describe the clinical pattern of disease To document diagnostic procedures performed for confirmation of diagnosis To describe first-line and salvage treatment regimens applied, guideline adherence, their efficacy and impact on patient survival To inform consensus guidelines To develop clinical screening and diagnostic procedures Set up of a collection of isolates with molecular characterization and evaluation of resistance genes

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Invasive Candidiases

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Cultural, histopathological, antigen or DNA evidence of invasive fungal infection with Candida species. * Hepatosplenic candidiasis with signs of disseminated Candida infection without culture, histological or microscopic evidence * Case control Matching procedure for controls: In part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital). Controls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization Exclusion Criteria: \- Colonization or other non-invasive infection, including superficial skin infections, candiduria without dissemination or Candida spp. in stool.

Locations (1)

University Hospital Cologne

Cologne, North Rhine-Westphalia, Germany

RECRUITING

Outcomes

Primary Outcomes

Incidence

To describe the global incidence of invasive Candida infection

Time frame: up to 100 weeks

Mortality

To describe the global mortality of invasive Candida infection

Time frame: up to 100 weeks

Molecular characteristics of Candida auris

To describe the molecular characteristics of Candida auris

Time frame: At 90 Days from diagnosis

Susceptibility testing

To describe the susceptibility of Candida auris

Time frame: At 90 Days from diagnosis

Resistance development

To describe the resistance development of Candida auris

Time frame: up to 100 weeks

Secondary Outcomes

Treatment efficacy of invasive candida infections

Number of participants with treatment failure

Time frame: At 90 Days from diagnosis

Treatment efficacy of invasive candida infections

Number of participants with stable disease

Time frame: At 90 Days from diagnosis

Treatment efficacy of invasive candida infections

Number of participants with partial response

Time frame: At 90 Days from diagnosis

Treatment efficacy of invasive candida infections

Central Contacts

Oliver Cornely, MD

CONTACT

+49 221 478 oliver.cornely@uk-koeln.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.